News - Appointments

Cristina Csimma has become chair of the board of directors of Finland-based Forendo Pharma Ltd as the company advances development of its lead compound for endometriosis.

Julian Gough, co-founder and chief scientific officer of Mogrify Ltd, has received the Academic Entrepreneur of the Year award from Cambridge Enterprise, the commercialisation arm of the University of Cambridge.

Thomas Taapken, a senior manager with venture capital experience, has been named chief financial officer, effective 1 October, of InflaRx NV in Germany as the company starts a Phase 3 trial of its lead product for

UK-based Silence Therapeutics Plc has appointed Mark Rothera as president and chief executive officer to lead development of its prospective siRNA therapeutics.

Mariola Söhngen has joined Proteome Sciences Plc as a director and chief executive officer, taking over from the interim CEO Ian Pike who continues as chief scientific officer.

Yilmaz Mahshid is to join the Swedish biotech company Medivir AB as chief executive officer, replacing Uli Hacksell, who will stay on the board of directors.

Ravi Rao has joined Sobi (Swedish Orphan Biovitrum AB) as its new head of research and development, replacing Milan Zdravkovic who is leaving the company.

Sven Rohmann, a medical doctor and biotech executive, has been appointed chief executive of Immunicum AB to lead clinical development of the Swedish company’s cell-based therapy for cancer.

Neil Bell, an expert in clinical development, has joined Avacta Life Sciences Ltd as chief development officer to manage human studies of the company’s lead drug, a pro-doxorubicin compound.

Erich Schlick, a venture capitalist and industrialist, has been appointed chair of the board of directors of Switzerland-based NBE-Therapeutics GmbH which is developing antibody-drug conjugates. He is currently a general partner and managing director at Wellington Partners in Munich.